[{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Bisoprolol Fumarate","moa":"||ADRB1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Athena Pharmaceutiques","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Athena Pharmaceutiques \/ ","highestDevelopmentStatusID":"12","companyTruncated":"Athena Pharmaceutiques \/ "},{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Athena Pharmaceutiques","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Dispersible","sponsorNew":"Athena Pharmaceutiques \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Athena Pharmaceutiques \/ Not Applicable"},{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved","graph3":"Athena Pharmaceutiques","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Dispersible","sponsorNew":"Athena Pharmaceutiques \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Athena Pharmaceutiques \/ Not Applicable"},{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"NFL Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"NFL-301","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Athena Pharmaceutiques","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Athena Pharmaceutiques \/ NFL Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Athena Pharmaceutiques \/ NFL Biosciences"}]

Find Clinical Drug Pipeline Developments & Deals by Athena Pharmaceutiques

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Ondansetron

                          Therapeutic Area : Gastroenterology

                          Study Phase : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Ondansetron Oro-Dispersible Tablet is pleasant and convenient as a tablet that melts in mouth and can be administered anytime anywhere with or without water,is used alone or with other medications to prevent nausea and vomiting caused by cancer drug trea...

                          Brand Name : Ondansetron-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 15, 2022

                          Lead Product(s) : Ondansetron

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Athena Company Banner

                          02

                          Lead Product(s) : NFL-301

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Preclinical

                          Sponsor : NFL Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          Details : Under the terms of the agreement, ATHENA Pharmaceutiques will manage the development and manufacturing of NFL-301, a natural drug candidate from NFL Biosciences aimed at reducing alcohol consumption, while NFL Biosciences will draw up and lead the clinic...

                          Brand Name : NFL-301

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 02, 2022

                          Lead Product(s) : NFL-301

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : NFL Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          Athena Company Banner

                          03

                          Lead Product(s) : Bisoprolol Fumarate,Aspirin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Study Phase : Approved

                          Sponsor :

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          Details : ATHENA Pharmaceutiques has acquire the Bisoprolol + Aspirin Capsules dossier as well as the patent for this product. It is a fixed dose combination of two reference agents improving compliance and adherence to treatment in the secondary prevention of car...

                          Brand Name : Bisoprolol/Aspirin-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 15, 2021

                          Lead Product(s) : Bisoprolol Fumarate,Aspirin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor :

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          Athena Company Banner

                          04

                          Lead Product(s) : Levocetirizine Dihydrochloride

                          Therapeutic Area : Immunology

                          Study Phase : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Levocetirizine ODT is second-generation piperazine derivative with potent H1-selective antihistaminic activity,n Improved oral bioavailability and onset of action vs. conventional oral slide form by avoiding hepatic first-pass effect.

                          Brand Name : Levocetirizine-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 12, 2020

                          Lead Product(s) : Levocetirizine Dihydrochloride

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Athena Company Banner